Literature DB >> 2943536

Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease.

J M Aerts, W E Donker-Koopman, M Koot, J A Barranger, J M Tager, A W Schram.   

Abstract

Glucocerebrosidase is present in considerable amounts in human urine. The enzyme is stable in concentrated urine for several days when stored at 0 degrees C. Like tissue glucocerebrosidase, the urinary enzyme is inhibited by conduritol B-epoxide and hydrolyses not only glucocerebroside but also the synthetic substrate 4-methyl-umbelliferyl-beta-D-glucoside. The enzyme is deficient in urine from patients with Gaucher disease (type 1). It is possible to discriminate completely between patients with type 1 Gaucher disease and control subjects by measuring the ratio glucocerebrosidase/beta-hexosaminidase in urine. The value of this ratio (mean +/- SE) with the synthetic substrates 4-methylumbelliferyl-beta-glucoside and p-nitrophenyl-beta-N-acetylglucosaminide, respectively, was 34.2 +/- 3.7 (n = 24) in the controls and 2.1 +/- 0.9 (n = 21) in the patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943536     DOI: 10.1016/0009-8981(86)90231-7

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

Review 1.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

2.  Nicotiana benthamiana α-galactosidase A1.1 can functionally complement human α-galactosidase A deficiency associated with Fabry disease.

Authors:  Kassiani Kytidou; Jules Beekwilder; Marta Artola; Eline van Meel; Ruud H P Wilbers; Geri F Moolenaar; Nora Goosen; Maria J Ferraz; Rebecca Katzy; Patrick Voskamp; Bogdan I Florea; Cornelis H Hokke; Herman S Overkleeft; Arjen Schots; Dirk Bosch; Navraj Pannu; Johannes M F G Aerts
Journal:  J Biol Chem       Date:  2018-04-19       Impact factor: 5.157

Review 3.  Alglucerase. A review of its therapeutic use in Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

4.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Authors:  C E Hollak; S van Weely; M H van Oers; J M Aerts
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

5.  Glycomimetic affinity-enrichment proteomics identifies partners for a clinically-utilized iminosugar.

Authors:  Isa N Cruz; Conor S Barry; Holger B Kramer; C Celeste Chuang; Sarah Lloyd; Aarnoud C van der Spoel; Frances M Platt; Min Yang; Benjamin G Davis
Journal:  Chem Sci       Date:  2013-07-08       Impact factor: 9.825

Review 6.  Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.

Authors:  Johannes M F G Aerts; Wouter W Kallemeijn; Wouter Wegdam; Maria Joao Ferraz; Marielle J van Breemen; Nick Dekker; Gertjan Kramer; Ben J Poorthuis; Johanna E M Groener; Josanne Cox-Brinkman; Saskia M Rombach; Carla E M Hollak; Gabor E Linthorst; Martin D Witte; Henrik Gold; Gijs A van der Marel; Herman S Overkleeft; Rolf G Boot
Journal:  J Inherit Metab Dis       Date:  2011-03-29       Impact factor: 4.982

Review 7.  Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.

Authors:  Lunawati L Bennett; Kelsey Turcotte
Journal:  Drug Des Devel Ther       Date:  2015-08-18       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.